Irritable Bowel Syndrome Research Today is a free monthly online journal that collates and summarizes the latest research about Irritable Bowel Syndrome, including details on treatment, symptoms, digestion, nutrition, diet, drugs.

Recent developments in the therapy of irritable bowel syndrome.

Saad RJ, Chey WD

Division of Gastroenterology, Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA.

There is tremendous activity and excitement in the arena of drug development for the treatment of the irritable bowel syndrome (IBS). Pharmacologic therapy has been largely limited to gut acting therapeutic agents including antidiarrheals, laxatives and antispasmodics that primarily target individual symptoms. Various antidepressants have gained popularity although their efficacy in clinical trials has been modest and their clinical utility is limited by untoward side effects. Serotonergic agents have demonstrated efficacy on the global symptoms of IBS; however, recent concerns about safety have severely limited their use. Recent discoveries regarding the pathophysiology of IBS have revealed numerous potential therapeutic targets. Agents under development include newer serotonergic agents and antidepressants; chloride channel, guanylate cyclase, opioid and motilin receptor ligands; various central, peripheral and autonomic neural receptor ligands; and gut immune modulators.

Published 30 January 2008 in Expert Opin Investig Drugs, 17(2): 117-30.
Full-text of this article is available online (may require subscription).

© 2004-2008 Irritable Bowel Syndrome Research Today. All Rights Reserved.